Abbott Laboratories

Abbott Laboratories FCF/Debt

The Free Cash Flow to Debt Ratio of Abbott Laboratories (ABT) as of Nov 19, 2026 is 49.08 %. In the previous year, Free Cash Flow to Debt Ratio was 41.58 % — a change of 18.05% (higher).

FCF/Debt

49.08 %

YoY

18.05%

Last updated:

Free Cash Flow to Debt Ratio of Abbott Laboratories is 2025 49.08 % . Free Cash Flow to Debt Ratio of Abbott Laboratories was 2024 41.58 % . It decreases by 18.05% higher compared to the previous year.

The Abbott Laboratories FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
25.07 USD
Jan 1, 2019
23.55 USD
Jan 1, 2020
28.78 USD
Jan 1, 2021
44.92 USD
Jan 1, 2022
43.49 USD
Jan 1, 2023
31.87 USD
Jan 1, 2024
41.58 USD
Jan 1, 2025
49.08 USD
The Abbott Laboratories FCF/Debt history
YEARFCF/DebtYoY
49.08 %+18.05%
41.58 %+30.45%
31.87 %-26.71%
43.49 %-3.20%
44.92 %+56.10%
28.78 %+22.20%
23.55 %-6.07%
25.07 %+57.87%
15.88 %+67.87%
9.46 %-54.12%
20.62 %-37.85%
33.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Abbott Laboratories Stock analysis

What does Abbott Laboratories do? Abbott Laboratories is one of the largest companies in the healthcare industry worldwide. The company was founded in 1888 by Dr. Wallace C. Abbott, who aimed to develop innovative and high-quality medical products that would improve people's lives and treat illnesses. Abbott Laboratories' business model is based on the discovery, development, manufacturing, and marketing of healthcare products. These range from pharmaceuticals to diagnostic devices. The company operates in various areas, including pharmaceuticals, nutrition, diagnostics, medical technology, and animal health. In the pharmaceutical field, Abbott Laboratories is a leading provider of generic drugs as well as innovative medications specialized in treating conditions such as Parkinson's disease, cancer, or hypertension. The company is particularly known for developing medications focused on the medical needs of women, such as hormone replacement therapy or birth control pills. In the nutrition field, Abbott Laboratories leads in the development of food and supplements for specific target groups, such as premature infants, cancer patients, or those with digestive problems. Best-selling products include Similac baby formula and Ensure, a nutritional supplement for older adults. In the diagnostics field, Abbott Laboratories develops and manufactures medical diagnostic devices and systems for patient monitoring. This includes blood glucose meters, blood pressure monitors, test strips, and laboratory systems for diagnosing diseases such as diabetes, HIV, or hepatitis. Abbott Laboratories is also a significant player in the medical technology field. The company produces and distributes medical devices such as pacemakers, stents, or artificial joints. These are typically used by doctors and hospitals to optimize patient treatment. In the animal health field, Abbott Laboratories offers a wide range of products and services for agricultural farms and veterinarians. This includes animal medications, pet food, diagnostics, and other services aimed at maintaining the health and well-being of livestock. Over the years, Abbott Laboratories has received numerous awards for its products and achievements. The company is committed to improving the quality of life for people worldwide and contributes to optimizing healthcare. Abbott Laboratories is among the top 15 leading pharmaceutical and healthcare companies worldwide and currently employs around 103,000 people in over 160 countries. Abbott Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Abbott Laboratories stock

Free Cash Flow to Debt Ratio of Abbott Laboratories is 49.08 % in 2025.

Free Cash Flow to Debt Ratio of Abbott Laboratories changed from 41.58 % to 49.08 %, representing a 18.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Abbott Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Abbott Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Abbott Laboratories

All Key Metrics — Abbott Laboratories